Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon alfa for macular degeneration

S L Williford1, T King

  • 1Womack Army Medical Center, Ft Bragg, NC 28307, USA.

The Annals of Pharmacotherapy
|June 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Tooth Loss Lead to School Bullying? Evidence from the Longitudinal Study of Australian Children.

JDR clinical and translational research·2025
Same author

Longitudinal Trajectories of Dental Attendance in Australian Adults.

Journal of dental research·2025
Same author

Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial.

Contemporary clinical trials·2024
Same author

Correction: Evaluation of a workplace suicide prevention program in the Australian manufacturing industry: protocol for a cluster-randomised trial of MATES in manufacturing.

BMC psychiatry·2023
Same author

Evaluation of a workplace suicide prevention program in the Australian manufacturing industry: protocol for a cluster-randomised trial of MATES in manufacturing.

BMC psychiatry·2022
Same author

Acute kidney injury in 18 cats after subcutaneous meloxicam and an update on non-steroidal anti-inflammatory drug usage in feline patients in Australia.

Australian veterinary journal·2022

Interferon alfa offers limited benefit for choroidal neovascularization (CNV) in macular degeneration. However, it shows potential for treating various retinal vascular conditions, including hemangiomas and retinopathy of prematurity.

Area of Science:

  • Ophthalmology
  • Medical Research
  • Retinal Diseases

Background:

  • Choroidal neovascularization (CNV) is a significant cause of vision loss.
  • Interferon alfa is a biologic agent with immunomodulatory properties.
  • The efficacy of interferon alfa in various ocular conditions requires clarification.

Purpose of the Study:

  • To evaluate the clinical effectiveness of interferon alfa in treating CNV secondary to macular degeneration.
  • To explore the potential utility of interferon alfa in other retinal vascular disorders.

Main Methods:

  • Review of clinical studies assessing interferon alfa treatment.
  • Analysis of patient outcomes in different ophthalmological conditions.

Main Results:

Related Experiment Videos

  • Interferon alfa demonstrated minimal benefit for CNV in macular degeneration.
  • Preliminary evidence suggests potential efficacy in treating choroidal and retinal hemangiomas.
  • Interferon alfa may be beneficial for diabetic retinopathy, post-vein occlusion retinopathy, and retinopathy of prematurity.

Conclusions:

  • Interferon alfa is not recommended for CNV associated with macular degeneration.
  • Further research is warranted to confirm the therapeutic role of interferon alfa in specific retinal vascular diseases.